vimarsana.com

Latest Breaking News On - Pisa university hospital - Page 1 : vimarsana.com

Durvalumab regimen extends PFS in certain patients with liver cancer

Durvalumab regimen extends PFS in certain patients with liver cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
nationaltribune.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationaltribune.com.au Daily Mail and Mail on Sunday newspapers.

Imfinzi and Bevacizumab Hit Endpoint in Liver Cancer Trial

Imfinzi and Bevacizumab Hit Endpoint in Liver Cancer Trial
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.